ANP32A and prostate cancer: Most of the studies show that PHAP1 functions as a tumour suppressor in human breast cancer, pancreatic cancer and non‐small‐cell lung cancer.7, 8, 9 However, other reports demonstrate increased PHAP1 expression is linked to hepatocellular carcinoma, colorectal cancer, prostate cancers and oral squamous cell carcinoma,10, 11, 12, 13, 14 suggesting PHAP1 can also promote cancers.